Gilead Sciences Inc (GILD)
Drugs • Health Care
Percentage
Change
| Feb 16 | Feb 17 | Feb 18 | Feb 19 | Feb 20 | Feb 21 | Feb 22 | Feb 23 | Feb 24 | Feb 25 | Feb 26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 29,443 | ||||||||||
U.S. | 20,876 | ||||||||||
Rest of World | 3,503 | ||||||||||
Europe | 5,064 |
| Feb 24 | Feb 25 | Feb 26 | |
|---|---|---|---|
Total Revenue | 29,435 | ||
Tecartus | 344 | ||
Total HIV | 20,752 | ||
Other HIV | 500 | ||
Symtuza - Revenue share | 495 | ||
Total Liver Disease | 3,217 | ||
Other Liver Disease | 874 | ||
Sofosbuvir/Velpatasvir | 1,272 | ||
Vemlidy | 1,070 | ||
Veklury | 911 |
| Feb 26 | |
|---|---|
Property, plant and equipment | 5,606 |
Gross property, plant and equipment | 8,302 |
Land | 561 |
Buildings and improvements | 4,622 |
Machinery and equipment | 1,241 |
Capitalized computer software | 666 |
Construction in progress title | 745 |
Other property, plant and equipment | 466 |
Accumulated depreciation, depletion and amortization | -2,696 |
| Feb 26 | |
|---|---|
Intangible assets | 16,978 |
Finite-lived intangible assets | 14,678 |
Intangible asset – sofosbuvir | 2,272 |
Intangible asset – axicabtagene ciloleucel | 3,983 |
Trodelvy | 7,566 |
Hepcludex | 430 |
Other | 428 |
Indefinite-lived intangible assets | 2,300 |
| Feb 13 | Feb 14 | Feb 15 | Feb 16 | Feb 17 | Feb 18 | Feb 19 | Feb 20 | Feb 21 | Feb 22 | Feb 23 | Feb 24 | Feb 25 | Feb 26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | 24,000 | |||||||||||||
Due in 1 Year | 2,750 | |||||||||||||
Due in 2 Years | 2,000 | |||||||||||||
Due in 4 Years | 750 | |||||||||||||
Due in 5 Years | 1,000 | |||||||||||||
Due in more than 5 Years | 17,500 |
| Feb 20 | Feb 21 | Feb 22 | Feb 23 | Feb 24 | Feb 25 | Feb 26 | |
|---|---|---|---|---|---|---|---|
Total | 698 | ||||||
Due in 1 Year | 121 | ||||||
Due in 2 Years | 99 | ||||||
Due in 3 Years | 87 | ||||||
Due in 4 Years | 75 | ||||||
Due in 5 Years | 73 | ||||||
Due in more than 5 Years | 243 |